COVID-19: Therapeutics and Their Toxicities.
Article Details
- CitationCopy to clipboard
Chary MA, Barbuto AF, Izadmehr S, Hayes BD, Burns MM
COVID-19: Therapeutics and Their Toxicities.
J Med Toxicol. 2020 Apr 30. pii: 10.1007/s13181-020-00777-5. doi: 10.1007/s13181-020-00777-5.
- PubMed ID
- 32356252 [ View in PubMed]
- Abstract
SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is causing the COVID-19 pandemic. There is no current standard of care. Clinicians need to be mindful of the toxicity of a wide variety of possibly unfamiliar substances being tested or repurposed to treat COVID-19. The United States Food and Drug Administration (FDA) has provided emergency authorization for the use of chloroquine and hydroxychloroquine. These two medications may precipitate ventricular dysrhythmias, necessitating cardiac and electrolyte monitoring, and in severe cases, treatment with epinephrine and high-doses of diazepam. Recombinant protein therapeutics may cause serum sickness or immune complex deposition. Nucleic acid vaccines may introduce mutations into the human genome. ACE inhibitors and ibuprofen have been suggested to exacerbate the pathogenesis of COVID-19. Here, we review the use, mechanism of action, and toxicity of proposed COVID-19 therapeutics.
DrugBank Data that Cites this Article
- Drugs
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Hydroxychloroquine Cytochrome P450 2C8 Protein Humans UnknownSubstrateDetails Hydroxychloroquine Cytochrome P450 2D6 Protein Humans UnknownSubstrateInhibitorDetails Hydroxychloroquine Cytochrome P450 3A4 Protein Humans UnknownSubstrateDetails